Beijing Danatlas Pharmaceutical Technology Co. Ltd. has divulged DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described pyrrolobenzodiazepine compounds reported to be useful for the treatment of cancer.

Amgen Inc. has synthesized GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Genzyme Corp. (Sanofi Genzyme) has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis and Parkinson’s disease.

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Genesis Therapeutics Inc. has divulged phosphatidylinositol 3-kinase alpha (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.

Matchpoint Therapeutics Inc. has synthesized new diazepino-thieno-quinoxaline compounds acting as MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.

Nimbus Saturn Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety linked via a linker.

Frontier Medicines Corp. has disclosed GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Septerna Inc. has divulged compounds acting as mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of asthma, cancer, multiple sclerosis, obesity, osteoarthritis, psoriasis, rheumatoid arthritis and ulcerative colitis, among others.